Does Pharmaceutical Industry Boost Economic Growth? A Competitiveness-Related Approach

Pharmaceutical industry is an important source of growth and competitiveness in many advanced economies, especially in USA, Japan and several European countries. However, related literature is scarce, there are only a few studies which have analyzed the relationship between growth and pharmaceutical industry from a trade-related perspective. This study aims to analyze the relationship between pharmaceutical industry exports and GDP. In this context, firstly the Revealed Comparative Advantage Index of all countries in pharmaceutical industry exports are calculated. This index revealed that 27 countries in the world are specialized in pharmaceutical exports by 2014. Then, panel data models are specified to test the relationship between pharmaceutical industry exports and GDP & GDP per capita in these countries for 2000-2014 period. Results indicate that pharmaceutical exports of these specialized countries effect both GDP and GDP per capita positively. High levels of export competitiveness in this particular industry which heavily relies on the discovery and production of new drugs/medical products also contribute to the advancement of economy.

İlaç Endüstrisi Ekonomik Büyümeyi Yükseltiyor mu? Rekabet Gücü Açısından Bir Yaklaşım

İlaç endüstrisi, başta ABD, Japonya ve bazı Avrupa ülkeleri olmak üzere birçok gelişmiş ekonomide büyümenin ve rekabet gücünün önemli bir kaynağıdır. Buna karşın ilgili literatür oldukça sınırlı olup, ilaç endüstrisi ile büyüme arasındaki ilişkiyi ticaretle bağlantılı olarak analiz eden az sayıda çalışma bulunmaktadır. Bu çalışmanın amacı, ilaç endüstrisi ihracatı ile GSYH arasındaki ilişkiyi analiz etmektir. Bu çerçevede öncelikle ülkelerin Açıklanmış Karşılaştırmalı Üstünlük Endeksi hesaplanmıştır. Buna göre, 2014 yılında dünyada 27 ülke ilaç endüstrisi ticaretinde uzmanlaşmıştır. Daha sonra, panel veri yöntemleri kullanılarak, bu ülkelerde 2000-2014 dönemi için, ilaç endüstrisi ihracatı ile GSYH ve kişi başına düşen GSYH değişkenleri arasındaki ilişki test edilmiştir. Sonuçlar, ilaç endüstrisinde uzmanlaşmış ülkelerin bu alandaki ihracatı ile GSYH ve kişi başına düşen GSYH arasında pozitif yönlü bir ilişkiyi göstermektedir. Ayrıca, büyük ölçüde yeni ilaçların/ürünlerin buluşuna ve geliştirilmesine dayanan bu spesifik endüstrinin ihracatında uzmanlaşma düzeyinin yüksek olması da, GSYH’yi ve kişi başına düşen GSYH’yi artırmaktadır.

Kaynakça

Abbott, F. M. 2005. The WTO medicines decision: World pharmaceutical trade and the protection of public health. American Journal of International Law, 99(2), 317. Doi. 10.2307/1562501

Barro, R. 1996. Health and economic growth, Mimeo. Cambridge, MA: Harvard University.

Barro, R., & Lee, J. 1994. Sources of economic growth. Carnegie-Rochester Conference Series on Public Policy 40, 1– 46.

Barro, R., & Sala-i Martin, X. 1995. Economic growth. New York: McGraw-Hill.

Bloom, D. E., Canning, D., & Sevilla, J. 2004. The effect of health on economic growth: a production function approach. World development, 32(1), 1-13.

Bloom, D. E., Canning, D., & Malaney, P. N. 2000. Demographic change and economic growth in Asia. Population and Development Review, 26(supp.), 257–290.

Blanc, L. 2015. The European Pharmaceutical Industry in a Global Economy: what drives EU exports of pharmaceuticals? No. 31. European Economic Studies Department, College of Europe.

Boldrin, M., & Levine, D. K. 2002. “The pharmaceutical Industry”. In: M. Boldrin and DK Levine, Against Intellectual Monopoly. Chapter 9, 212-242.

Boring, A. 2010. Does Foreign Patent Protection Increase the United States' Trade of Pharmaceuticals with Developing Countries. Unpublished paper.

Chaudhuri S. 2005. The WTO and India’s pharmaceutical industry: patent protection, TRIPS and developing countries. New Delhi: Oxford University Press.

Citeline. 2015. Citeline Pharma R&D Annual Review 2015. https://pharmaintelligence.informa.com/resources/productcontent/citeline-pharma-rd-annualreview-2015 (Accession: 02.09.2016)

Danzon, P. M., Nicholson, S., & Pereira, N. S. 2005. Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances. Journal of health economics, 24(2), 317-339. Doi. 10.3386/w9615

EFPIA. 2015. The Pharmaceutical Industry in Figures - Edition 2015. European Federation of Pharmaceutical Industries and Associations.

Ernst&Young. 2014. Biotechnology Industry Report 2014: Beyond borders, unlocking value. http://www.europabio.org/sites/default/files/facts/ey-beyond-borders-unlocking-value.pdf

Ernst&Young. 2015. Biotechnology Industry Report 2015: Beyond borders, reaching new heights. http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders-2015/$FILE/EY-beyond-borders-2015.pdf

European Commission. 2014. Pharmaceutical Industry: A Strategic Sector for the European Economy. Commission Staff Working Document, SWD (2014) 216 final/2.

European Commission. 2015. The 2015 EU R&D Industrial Investment Scoreboard. European Commission, Brussels. http://iri.jrc.ec.europa.eu/scoreboard15.html

EUROSTAT. 2016. Statistical Database. http://ec.europa.eu/eurostat. FDA. 2016. http://www.fda.gov (Accession: 12.02.2016)

Feenstra, Robert C., Robert Inklaar and Marcel P. Timmer. 2015. "The Next Generation of the Penn World Table." American Economic Review, 105(10), 3150-3182, available for download at www.ggdc.net/pwt. Doi. 10.15141/S5J01T

Gambardella, A., Orsenigo, L., & Pammolli, F. 2001. Global competitiveness in pharmaceuticals: A European perspective. Office for Official Publications of the European Communities.

González, Claudia Patricia Vacca, James F. Fitzgerald, and Joan Rovira. 2008. "Generics in Latin America: trends and regulation." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 6.1: 43-56. Doi. 10.1057/jgm.2008.32

Grabowski, H. G. 1990. Innovation and international competitiveness in pharmaceuticals. Evolving technology and market structure: Studies in Schumpeterian economics.

Grabowski, H. G. & R. Y. Wann. 2008. Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act. Journal of Law and Economics, 51, 377-406.

Hafner, T., & Popp, D. 2011. China and India as suppliers of affordable medicines to developing countries (No. w17249). National Bureau of Economic Research. Doi. 10.3386/w17249

Hernandez Guevara, Hector, et al. 2015. The 2015 EU Industrial R&D Investment Scoreboard. Institute for Prospective and Technological Studies, Joint Research Centre. Doi. 10.2791/15792

Hess, A. M., & Rothaermel, F. T. 2011. When are assets complementary? Star scientists, strategic alliances, and innovation in the pharmaceutical industry. Strategic Management Journal, 32(8), 895-909. Doi. 10.1002/smj.916

ITA (2017). International Trade Administration 2016 Top Markets Report Pharmaceuticals. http://trade.gov/topmarkets/pdf/Pharmaceuticals_Executive_Summary.pdf

ITC (International Trade Centre). (2016). Trade Competitiveness Map. http://legacy.intracen.org/marketanalysis/ canada/TradeCompetitivenessMap.aspx (Accession 03.01.2016).

Lehnhausen, A. K. 2017. Studies on Competition and Antitrust Issues in the Pharmaceutical Industry. Springer Gabler, Germany

Lichtenberg, F. R. 1998. Pharmaceutical innovation, mortality reduction, and economic growth. NBER Working Papers. No. w6569. National Bureau of Economic Research.

Liu, K. 2014. Human capital, social collaboration, and patent renewal within US pharmaceutical firms. Journal of management, 40(2), 616-636. Doi. 10.1177/0149206313511117

Mestre-Ferrandiz, J., Sussex, J., & Towse, A. 2012. The R&D cost of a new medicine. London: Office of Health Economics (www. fiercebiotech. com/press-releases/new-ohe-study-pharmaceutical-rd-costs-released.

Muratoğlu, G. & Muratoğlu, Y. 2016. Determinants of Export Competitiveness: Evidence from OECD Manufacturing. Journal of Economics and Political Economy, 3(1), 111-118.

Nusser M., Tischendorf, A. 2010. The Research-Based Pharmaceutical Industry as a Chance for the Business Location Germany. Berlin: Frauenhofer Gesellschaft.

Pharmaceutical Executive (2017). Pharm Exec's Top 50 Companies. Pharmaceutical Executive, Volume 36, Issue 6.

PhRMA (2017). The Pharmaceutical Research and Manufacturers of America. http://www.phrma.org/

Taylor, D. 2015. The Pharmaceutical Industry and the Future of Drug Development. In Issues in Environmental Science and Technology No. 41. Pharmaceutical in the Environment. Eds. R. E. Hester and R. M. Harrison. Doi. 10.1039/9781782622345-00001

Wilkman, M. 2012. Determinants of Swedish Pharmacutical Exports. Master Thesis. Jönköping University. Jönköping International Business School.

World Bank. 2016. World Development Indicators Database. http://databank.worldbank.org/data/databases.aspx.

WTO. 2016. Time Series on International Trade Database. http://stat.wto.org/StatisticalProgram/WSDBStatProgramHome.aspx?Language=E.

Kaynak Göster